Compare NVT & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVT | INSM |
|---|---|---|
| Founded | 1903 | 1988 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6B | 23.0B |
| IPO Year | 2017 | 2000 |
| Metric | NVT | INSM |
|---|---|---|
| Price | $168.37 | $102.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 24 |
| Target Price | $131.36 | ★ $201.17 |
| AVG Volume (30 Days) | 1.9M | ★ 4.4M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.61% | N/A |
| EPS Growth | ★ 118.78 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $3,893,100,000.00 | N/A |
| Revenue This Year | $19.44 | $182.31 |
| Revenue Next Year | $12.41 | $65.19 |
| P/E Ratio | $211.89 | ★ N/A |
| Revenue Growth | ★ 29.51 | N/A |
| 52 Week Low | $69.04 | $90.39 |
| 52 Week High | $184.64 | $212.75 |
| Indicator | NVT | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 51.76 | 45.73 |
| Support Level | $152.61 | $98.90 |
| Resistance Level | $176.50 | $166.81 |
| Average True Range (ATR) | 7.51 | 5.41 |
| MACD | 0.17 | 1.39 |
| Stochastic Oscillator | 49.34 | 72.79 |
NVent is a leading global provider of electrical connection and protection solutions that touch a broad range of end markets, including infrastructure, industrial, commercial, and residential. NVent designs, manufactures, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.